Algo-dysfunctional syndromes: A critical digest of the recent literature

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages S102-S108

  Talotta, Rossella ^a   Atzeni, Fabiola ^b   Bazzichi, Laura ^c   Giacomelli, Camillo ^c   Di Franco, Manuela ^d   Salaffi, Fausto ^e   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Chronic fatigue syndrome; Fibromyalgia; Irritable bowel syndrome

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; HYDROCORTISONE; IMMUNOGLOBULIN; MELATONIN; MEMANTINE;

ACUPUNCTURE; ALGO DYSFUNCTIONAL SYNDROME; BALNEOTHERAPY; CENTRAL NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; EATING HABIT; ENVIRONMENTAL FACTOR; FIBROMYALGIA; HEREDITY; HORMONE SYNTHESIS; HUMAN; HYPNOSIS; INFECTION; INFLAMMATION; IRRITABLE COLON; KINESIOTHERAPY; MULTICENTER STUDY (TOPIC); PATHOGENESIS; PERIPHERAL NERVE; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SYNDROME; FATIGUE SYNDROME, CHRONIC; IRRITABLE BOWEL SYNDROME; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

FATIGUE SYNDROME, CHRONIC; FIBROMYALGIA; HUMANS; IRRITABLE BOWEL SYNDROME; RISK FACTORS; TREATMENT OUTCOME;

EID: 84929284633     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. De VEGA WC, VERNON SD, McGOWAN PO: DNA methylation modification associated with chronic fatigue syndrome. PLOS One 2014; 9: e104757.
2. NIJS J, NEES A, PAUL L et al.: Altered immune response to exercise in patients with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic literature review. Exerc Immunol Rev 2014; 20: 94-116.
3. NEU D, MAIRESSE O, MONTANA X et al.: Dimensions of pure chronic fatigue: psychophysical, cognitive and biological correlates in the chronic fatigue syndrome. Eur J Appl Physiol 2014; 114: 1841-51.
4. BRENU EW, HUTH TK, HARDCASTLE SL et al.: Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol 2014; 26: 233-42.
5. MORRIS G, MAES M: Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis 2014; 29: 19-36.
6. RASA S, NORA-KRUKLE Z, CHAPENKO S et al.: No evidence of XMRV provirus sequences in patients with myalgic encephalomyelitis/ chronic fatigue sindrome and individuals with unspecified encephalopathy. New Microbiologica 2014; 37: 17-24.
7. MAGGI F, BAZZICHI L, SERNISSI F et al.: Absence of xenotropic murine leukemia virus-related virus in Italian patients affected by chronic fatigue syndrome, fibromyalgia, or rheumatoid arthritis. Int J Immunopathol Pharmacol 2012; 25: 523-9.
8. BARAH F, WHITESIDE S, BATISTA S et al.: Neurological aspects of human parvovirus B19 infection: a systematic review. Rev Med Virol 2014; 24: 154-68.
9. HANEVIK K, WENSAAS KA, RORTVEIT G et al.: Irritable bowel syndrome and chronic fatigue six years after Giardia infection: a controlled prospective cohort study. Clin Infect Dis 2014; 12.
10. HALLIEZ MC, BURET AG: Extra-intestinal and long term consequences of Giardia duodenalis infections. World J Gastroenterol 2013; 19: 8974-85.
11. TSAI SY, YANG TY, CHEN HJ et al.: Increased risk of chronic fatigue syndrome following herpes zoster: a population-based study. Eur J Clin Microbiol Infect Dis 2014; 33: 1653-9.
12. MILLER RR, GARDY JL, TANG P et al.: A metagenomic approach to investigate the microbial causes of myalgic encephalomyelitis/ chronic fatigue syndrome: moving beyond XMRV. Fatigue 2013; 1: 185-9.
13. POWELL DJ, LIOSSI C, MOSS-MORRIS R et al.: Unstimulated cortisol secretory activity in everyday life and its relationship with fatigue and chronic fatigue syndrome: a systematic review and subset meta-analysis. Psychoneuroendocrinology 2013; 38: 2405-22.
14. IFUKU M, HOSSAIN SM, NODA M et al.: Induction of interleukin-1ß by activated microglia is a prerequisite for immunologically induced fatigue. Eur J Neurosci 2014.
15. MILLER AH, JONES JF, DRAKE DF et al.: Decreased basal ganglia activation in subjects with chronic fatigue syndrome: association with symptoms of fatigue. PLoS One 2014; 9: e98156.
16. VALERO S, SÁEZ-FRANCÀS N, CALVO N et al.: The role of neuroticism, perfectionism and depression in chronic fatigue syndrome. A structural equation modeling approach. Compr Psychiatry 2013; 54: 1061-7.
17. SÁEZ-FRANCÀS N, VALERO S, CALVO N et al.: Chronic fatigue syndrome and personality: a case-control study using the alternative five factor model. Psychiatry Res 2014; 216: 373-8.
18. MIWA K: Cardiac dysfunction and orthostatic intolerance in patients with myalgic encephalomyelitis and a small left ventricle. Heart Vessels 2014.
19. WITHAM M, KENNEDY G, BELCH J et al.: Association between vitamin D status and markers of vascular health in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Int J Cardiol 2014; 174: 139-40.
20. ISASI C, TEJERINA E, FERNANDEZ-PUGA N et al.: Fibromyalgia and chronic fatigue syndrome caused by non-celiac gluten sensitivity. Reumatol Clin 2015; 11: 56-7.
21. JOHNSTON SC, BRENU EW, HARDCASTLE SL et al.: A comparison of health status in patients meeting alternative definitions for chronic fatigue syndrome/myalgic encephalomyelitis. Health Qual Life Outcomes 2014; 12: 64.
22. JASON LA, SUNNQUIST M, BROWN A et al.: Are myalgic encephalomyelitis and chronic fatigue syndrome different illnesses? A preliminary analysis. J Health Psychol 2014.
23. ADAMOWICZ JL, CAIKAUSKAITE I, FRIEDBERG F: Defining recovery in chronic fatigue syndrome: a critical review. Qual Life Res 2014.
24. SANTAMARINA-PEREZ P, EIROA-OROSA FJ, RODRIGUEZ-URRUTIA A et al.: Neuropsychological impairment in female patients with chronic fatigue syndrome: a preliminary study. Appl Neuropsychol Adult 2014; 21: 120-7.
25. ROWE PC, MARDEN CL, FLAHERTY MA et al.: Impaired range of motion of limbs and spine in chronic fatigue syndrome. J Pediatr 2014; 165: 360-6.
26. TOBBACK E, MARIMAN A, HEYTENS S et al.: A multidisciplinary network for the care of abnormal fatigue and chronic fatigue syndrome in the provinces of East and West Flanders in Belgium. Acta Clin Belg 2014.
27. TIRELLI U, LLESHI A, BERRETTA M et al.: Treatment of 741 Italian patients with chronic fatigue syndrome. Eur Rev Med Pharmacol Sci 2013; 17: 2847-52.
28. CAZZOLA M, ATZENI F, BOCCASSINI L et al.: Physiopathology of pain in rheumatology. Reumatismo 2014; 66: 4-13.
29. SMITH SB, REENILÄ I, MÄNNISTÖ PT et al.: Epistasis Between Polymorphisms in COMT, ESR1, and GCH1 Influences COMT Enzyme Activity and Pain. Pain 2014.
30. LEE YH, KIM JH, SONG GG: Association between the COMT Val158Met polymorphism and fibromyalgia susceptibility and fibromyalgia impact questionnaire score: a metaanalysis. Rheumatol Int 2014.
31. SOLAK O, ERDOGAN MO, YILDIZ H et al.: Assessment of opioid receptor μ1 gene A118G polymorphism and its association with pain intensity in patients with fibromyalgia. Rheumatol Int 2014; 34: 1257-61.
32. DOCAMPO E, ESCARAMÍS G, GRATACÒS M et al.: Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system. Pain 2014; 155: 1102-9.
33. BALKARLI A, SENGÜL C, TEPELI E et al.: Synaptosomal-associated protein 25 (Snap-25) gene polymorphism frequency in fibromyalgia syndrome and relationship with clinical symptoms. BMC Musculoskelet Disord 2014; 15: 191.
34. ANDERSEN HH, DUROUX M, GAZERANI P: MicroRNAs as modulators and biomarkers of inflammatory and neuropathic pain conditions. Neurobiol Dis 2014; 71C: 159-68.
35. ZANETTE SA, DUSSAN-SARRIA JA, SOUZA A et al.: Higher serum S100B and BDNF levels are correlated with a lower pressure-pain threshold in fibromyalgia. Mol Pain 2014; 10: 46.
36. BROWN CA, EL-DEREDY W, JONES AK: When the brain expects pain: common neural responses to pain anticipation are related to clinical pain and distress in fibromyalgia and osteoarthritis. Eur J Neurosci 2014; 39: 663-72.
37. MONTORO CI, DUSCHEK S, MUÑOZ LADRÓN DE GUEVARA C et al.: Aberrant cerebral blood flow responses during cognition: implications for the understanding of cognitive deficits in fibromyalgia. Neuropsychology 2014.
38. LOGGIA ML, BERNA C, KIM J et al.: Disrupted brain circuitry for pain-related reward/ punishment in fibromyalgia. Arthritis Rheumatol 2014; 66: 203-12.
39. LÓPEZ-SOLÀ M, PUJOL J, WAGER TD et al.: Altered fMRI responses to non-painful sensory stimulation in fibromyalgia patients. Arthritis Rheumatol 2014.
40. BERNIK M, SAMPAIO TP, GANDARELA L: Fibromyalgia comorbid with anxiety disorders and depression: combined medical and psychological treatment. Curr Pain Headache Rep 2013; 17: 358.
41. YENER M, ASKIN A, SOYUPEK F et al.: The evaluation of anxiety and depression status in spouses of sexually active reproductive women with fibromyalgia. Clin Exp Rheumatol 2015; 33 (Suppl. 88): S20-24.
42. BAZZICHI L, ROSSI A, GIACOMELLI C et al.: The influence of psychiatric comorbidity on sexual satisfaction in fibromyalgia patients. Clin Exp Rheumatol 2013; 31 (Suppl. 79): S81-5.
43. ALOK R, DAS SK, AGARWAL GG et al.: Problem-focused coping and self-efficacy as correlates of quality of life and severity of fibromyalgia in primary fibromyalgia patients. J Clin Rheumatol 2014; 20: 314-6.
44. GIANNOCCARO MP, DONADIO V, INCENSI A et al.: Small nerve fiber involvement in patients referred for fibromyalgia. Muscle Nerve 2014; 49: 757-9.
45. CARO XJ, WINTER EF: Evidence of abnormal epidermal nerve fiber density in fibromyalgia: clinical and immunologic implications. Arthritis Rheumatol 2014; 66: 1945-54.
46. SERRA J, COLLADO A, SOLÀ R et al.: Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol 2014; 75: 196-208.
47. KOLE AK, ROY R, KOLE DC: Musculoskeletal and rheumatological disorders in HIV infection: Experience in a tertiary referral center. Indian J Sex Transm Dis 2013; 34: 107-12.
48. OZSAHIN M, GONEN I, ERMIS F et al.: The prevalence of fibromyalgia among patients with hepatitis B virus infection. Int J Clin Exp Med 2013; 6: 804-8.
49. NUGRAHA B, KORALLUS C, KIELSTEIN H, GUTENBRUNNER C: CD3+CD56+natural killer T cells in fibromyalgia syndrome patients: association with the intensity of depression. Clin Exp Rheumatol 2013; 31(Suppl. 79): S9-15.
50. ISASI C, COLMENERO I, CASCO F et al.: Fibromyalgia and non-celiac gluten sensitivity: a description with remission of fibromyalgia. Rheumatol Int 2014; 34: 1607-12.
51. RODRIGO L, BLANCO I, BOBES J et al.: Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. Arthritis Res Ther 2014; 16: 421.
52. TOVOLI F, GIAMPAOLO L, CAIO G et al.: Fibromyalgia and coeliac disease: a media hype or an emerging clinical problem? Clin Exp Rheumatol 2013; 31 (Suppl. 79): S50-2.
53. GERDLE B, GHAFOURI B, ERNBERG M et al.: Chronic musculoskeletal pain: review of mechanisms and biochemical biomarkers as assessed by the microdialysis technique. J Pain Res 2014; 7: 313-26.
54. GERDLE B, LARSSON B, FORSBERG F et al.: Chronic widespread pain: increased glutamate and lactate concentrations in the trapezius muscle and plasma. Clin J Pain 2014; 30: 409-20.
55. BOKAREWA MI, ERLANDSSON MC, BJERSING J et al.: Smoking is associated with reduced leptin and neuropeptide y levels and higher pain experience in patients with fibromyalgia. Mediators Inflamm 2014; 2014: 627041.
56. OLIVAN-BLÁZQUEZ B, HERRERA-MERCADAL P, PUEBLA-GUEDEA M et al.: Efficacy of memantine in the treatment of fibromyalgia: a double-blind randomised controlled trial with 6-month follow-up. Pain 2014.
57. de ZANETTE SA, VERCELINO R, LASTE G et al.: Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 2014; 15: 40.
58. DI FRANCO M, IANNUCCELLI C: Complementary and alternative medicine in fibromyalgia: yes or no? Clin Exp Rheumatol 2013; 31 (Suppl. 79): S6-8.
59. PERROT S, RUSSELL IJ: More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: A meta-analysis examining six core symptoms. Eur J Pain 2014; 18: 1067-80.
60. SOARES RL: Irritable bowel syndrome: A clinical review. World J Gastroenterol 2014; 20: 12144-60.
61. SRIVASTAVA D, GHOSHAL U, MITTAL RD et al.: Associations between IL-1RA polymorphisms and small intestinal bacterial overgrowth among patients with irritable bowel syndrome from India. Neurogastroenterol Motil 2014.
62. CAMILLERI M, SHIN A, BUSCIGLIO I et al.: Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol 2014; 307: G508-16.
63. ZHANG ZF, DUAN ZJ, WANG LX et al.: The serotonin transporter gene polymorphism (5-HTTLPR) and irritable bowel syndrome: a meta-analysis of 25 studies. BMC Gastroenterol 2014; 14: 23.
64. AREESHI MY, HAQUE S, PANDA AK et al.: A serotonin transporter gene (SLC6A4) polymorphism is associated with reduced risk of irritable bowel syndrome in American and Asian populations: a meta-analysis. PLoS One 2013; 8: e75567.
65. QIN SY, JIANG HX, LU DH et al.: Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2013; 19: 9472-80.
66. LIN ZHANG, JIAN CHENG, XIAO-MING FAN: MicroRNAs: New therapeutic targets for intestinal barrier dysfunction. World J Gastroenterol 2014; 20: 5818-25.
67. FOURIE NH, PEACE RM, ABEY SK et al.: Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome. Exp Mol Pathol 2014; 96: 422-5.
68. de KIVIT S, TOBIN MC, FORSYTH CB et al.: Regulation of intestinal immune responses through TLR activation: implications for proand prebiotics. Front Immunol 2014; 5: 60.
69. de KIVIT S, TOBIN MC, DEMEO MT et al.: In vitro evaluation of intestinal epithelial TLR activation in preventing food allergic responses. Clin Immunol 2014; 154: 91-9.
70. JALANKA-TUOVINEN J, SALOJÄRVI J, SALONEN A et al.: Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2013.
71. ENGSBRO AL, STENSVOLD CR, VEDEL NIELSEN H et al.: Prevalence, incidence, and risk factors of intestinal parasites in Danish primary care patients with irritable bowel syndrome. Scand J Infect Dis 2014; 46: 204-9.
72. KROGSGAARD LR, ENGSBRO AL, STENSVOLD CR et al.: The Prevalence of Intestinal Parasites is not Greater Among Individuals with IBS: a Population-Based Case-Control Study. Clin Gastroenterol Hepatol 2014.
73. HAYES PA, FRAHER MH, QUIGLEY EM: Irritable bowel syndrome: the role of food in pathogenesis and management. Gastroenterol Hepatol (NY) 2014; 10: 164-74.
74. VICARIO M, GONZÁLEZ-CASTRO AM, MARTÍNEZ C et al.: Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations. Gut 2014.
75. O'MALLEY D, BUCKLEY MM, McKERNAN DP et al.: Soluble mediators in plasma from irritable bowel syndrome patients excite rat submucosal neurons. Brain Behav Immun 2014.
76. STILLING RM, DINAN TG, CRYAN JF: Microbial genes, brain&behaviour - epigenetic regulation of the gut-brain axis. Genes, Brain and Behavior 2014; 13: 69-86.
77. PELLISSIER S, DANTZER C, MONDILLON L et al.: Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One 2014; 9: e105328.
78. ZHU X, ZHU X, CHEN W et al.: The application of functional magnetic resonance imaging in an infant rat model of irritable bowel syndrome. Gastroenterol Res Pract 2014; 2014: 473846.
79. MELEINE M, MATRICON J: Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol 2014; 20: 6725-43.
80. BUCKLEY MM, O'MAHONY SM, O'MALLEY D: Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome. World J Gastroenterol 2014; 20: 8846-58.
81. ZHANG MM, LIU SB, CHEN T et al.: Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain. Mol Brain 2014; 7: 47.
82. HALMOS EP, POWER VA, SHEPHERD SJ et al.: A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75.e5.
83. PEYTON L, GREENE J: Irritable bowel syndrome: current and emerging treatment options. P T. 2014; 39: 567-78.
84. FORD AC, QUIGLEY EM, LACY BE et al.: Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014.
85. STEVENSON C, BLAAUW R, FREDERICKS E et al.: Randomized clinical trial: Effect of Lactobacillus plantarum 299v on symptoms of irritable bowel syndrome. Nutrition 2014; 30: 1151-7.
86. ANNAHÁZI A, RÓKA R, ROSZTÓCZY A et al.: Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20: 6031-43.
87. CHMIELEWSKA-WILKON D, REGGIARDO G, EGAN CG: Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial. World J Gastroenterol 2014; 20: 12283-91.
88. RYCHTER J, ESPÍN F, GALLEGO D et al.: Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide. Therap Adv Gastroenterol 2014; 7: 156-66.
89. FORD AC, QUIGLEY EM, LACY BE et al.: Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350-65.
90. YANG Y, CUI X, CHEN Y et al.: Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity. J Physiol Pharmacol 2014; 65: 349-57.
91. MISHRA SP, SHUKLA SK, PANDEY BL: A preliminary evaluation of comparative effectiveness of riluzole in therapeutic regimen for irritable bowel syndrome. Asian Pac J Trop Biomed 2014; 4 (Suppl. 1): S335-40.
92. LAN L, CHEN YL, ZHANG H et al.: Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety. World J Gastroenterol 2014; 20: 11422-8.
93. YU SW, RAO SS: Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol 2014; 7: 193-205.
94. PIMENTEL M, CHANG C, CHUA KS et al.: Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014; 59: 1278-85.
95. FASSOV J, BROCK C, LUNDBY L et al.: Sacral nerve stimulation changes rectal sensitivity and biomechanical properties in patients with irritable bowel syndrome. Neurogastroenterol Motil 2014.